News Quantified

PSNL – personalis, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]

Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors

Personalis (NASDAQ:PSNL) was upgraded by analysts at Wall Street Zen

New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer

Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds [Yahoo! Finance]

-12.3%

BEAT

-21.9%

BEAT

21.0%

BEAT

-2.4%

BEAT

Form 8-K Personalis, Inc. For: Nov 28

Form 424B5 Personalis, Inc.

Form 4 Personalis, Inc. For: Nov 25 Filed by: Tachibana Aaron

Form 144 Personalis, Inc. Filed by: Tachibana Aaron

Form 8-K Personalis, Inc. For: Nov 24

Top News Gainers

6/19 Form 3 Personalis, Inc. For: Jun 19 Filed by: Abingworth LLP 20.2%

3/19 Form 4 Personalis, Inc. For: Mar 17 Filed by: West John Stephen 17.0%

3/27 Form 4 Personalis, Inc. For: Mar 25 Filed by: Chen Richard 16.6%

3/25 Form 8-K Personalis, Inc. For: Mar 25 10.1%

4/3 Form DEF 14A Personalis, Inc. For: May 15 8.7%

3/18 Form 4 Personalis, Inc. For: Mar 16 Filed by: Tachibana Aaron 8.3%

11/12 Personalis, Inc. Expands Oncology Portfolio With the Launch of Cancer Whole Genome Sequencing Services 7.0%

12/5 Form 4 Personalis, Inc. For: Dec 03 Filed by: Chen Richard 6.9%

4/9 Personalis (NASDAQ: PSNL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.75 price target on the stock. 6.6%

4/23 Personalis to Announce First Quarter 2020 Financial Results on May 7, 2020 6.2%

Top News Decliners

8/13 Q2/2019 6/30/2019 EPS -0.890 ZacksConsensus -0.310 ActVsEst (0.580) - Miss -18.0%

3/11 Personalis to Announce Fourth Quarter and Full Year 2019 Financial Results on March 25, 2020 -15.8%

9/26 Form 8-K Personalis, Inc. For: Sep 25 -15.6%

10/1 2 Top Stocks That Aren't on Wall Street's Radar [The Motley Fool] -13.2%

11/13 Form 10-Q Personalis, Inc. For: Sep 30 -11.6%

9/9 Personalis, Inc. Enters Into Research Agreement With Invectys to Provide Comprehensive Tumor Immunogenomics Profiling for Clinical Trial -11.5%

9/26 Personalis (NASDAQ: PSNL) was upgraded by analysts at Bank of America Corp from a "neutral" rating to a "buy" rating. -9.4%

11/17 Personalis, Inc. to Present New Data at the AACR Tumor Immunology and Immunotherapy Conference -8.7%

7/15 Personalis (NASDAQ: PSNL) is now covered by analysts at Bank of America Corp. They set a "neutral" rating on the stock. -6.8%

2/11 Form 4 Personalis, Inc. For: Feb 07 Filed by: LUDLUM KEN -5.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day